Chlorpromazine Syrup Suppliers & Bulk Manufacturers
Available Forms: Oral Syrup
Available Strengths: 30 mg/mL
Reference Brands: Largactil® (EU); Thorazine®(US)
Category:
Antipsychotropic Drugs
Chlorpromazine syrup blocks dopamine D2 receptors, reducing psychotic symptoms like hallucinations and agitation. It’s used to treat schizophrenia, bipolar mania, severe behavioural issues in children, and intractable hiccups. The liquid form allows flexible dosing, making it ideal for pediatric, geriatric, or patients with difficulty swallowing tablets.
Chlorpromazine Syrup is available in Oral Syrup
and strengths such as 30 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Chlorpromazine Syrup is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Chlorpromazine Syrup can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Chlorpromazine syrup is FDA-approved in the United States for treating schizophrenia, severe behavioral disorders, nausea, and intractable hiccups. In the EU, it is available in select markets under national authorizations, primarily for pediatric and geriatric use. Regulatory requirements include GMP compliance, stability data for liquid dosage forms, and safety documentation addressing anticholinergic and sedative effects. U.S. submissions must follow FDA oral solution guidelines, including accurate dosing and child-resistant packaging. EU applications may require pharmacovigilance planning and pediatric-specific labeling. To explore dossier-ready Chlorpromazine syrup and alternative formulations, visit Pharmatradz.com — your global B2B pharma sourcing partner.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing